NEXTCURE INC(NASDAQ:NXTC) stock News

NXTC Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: NextCure

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

6 days ago - By: NextCure

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

2 months ago - By: NextCure

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: NextCure

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: The Motley Fool

NextCure (NXTC) Q2 Loss Widens 71%

3 months ago - By: NextCure

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: NextCure

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: Benzinga - Mentions: IVA PIII TTNP HCTI ...

12 Health Care Stocks Moving In Friday's Intraday Session

3 months ago - By: Benzinga - Mentions: CNC ZYXI XTLB SRPT ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

3 months ago - By: Stocktwits

NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment

3 months ago - By: NextCure

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

3 months ago - By: NextCure

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

4 months ago - By: Stocktwits - Mentions: VTI VXF

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline

4 months ago - By: NextCure

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

4 months ago - By: NextCure

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

5 months ago - By: NextCure

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

5 months ago - By: NextCure

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

5 months ago - By: Yahoo Finance - Mentions: GAP TAL GOOS GOOG ...

The Gap, Inc. (GAP) Is A “Star,” Says Jim Cramer

5 months ago - By: Yahoo Finance - Mentions: GOOS TAL AXP NVDA ...

Canada Goose Holdings Inc. (GOOS) Has Been “Terrific,” Says Jim Cramer

6 months ago - By: NextCure

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

6 months ago - By: NextCure

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

7 months ago - By: NextCure

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

7 months ago - By: NextCure

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

8 months ago - By: NextCure

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

8 months ago - By: NextCure

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

8 months ago - By: Stocktwits - Mentions: SHPH LPTX KURA ACET

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

9 months ago - By: NextCure

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

9 months ago - By: NextCure

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

11 months ago - By: NextCure

NEXTCURE INC (NXTC) Stock News

NXTC Latest News, Press Relases and Analysis

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NextCure (NXTC) Q2 Loss Widens 71%

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

The Gap, Inc. (GAP) Is A “Star,” Says Jim Cramer

Canada Goose Holdings Inc. (GOOS) Has Been “Terrific,” Says Jim Cramer

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Announces Acceptance of IND Application for LNCB74